血液灌流联合血液透析对尿毒症难治性高血压患者的疗效

目的 探讨血液灌流联合血液透析对尿毒症难治性高血压患者的疗效.方法 将我院收治的46例尿毒症顽固性高血压患者按数字表法随机分为血液灌流组(n=23)和血液透析组(n=23).检测患者治疗前后血浆肾素活性、血管紧张素Ⅱ、甲状旁腺激素水平,观察血压变化情况.采用t检验或卡方检验进行数据统计.结果 治疗8周后,血液灌流组血浆肾素活性、血管紧张素Ⅱ、甲状旁腺激素及血压水平较治疗前有明显变化,差异有统计学意义(P＜0.05);而血液透析组治疗前后上述指标差异无统计学意义(P＞0.05).治疗后,两组上述指标差异有统计学意义(P＜0.05).结论 血液灌流联合血液透析能有效清除血浆肾素和血管紧张素,更好地控制尿毒症患者的难治性高血压.     

组合型人工肾治疗尿毒症患者皮肤瘙痒的效果观察

目的探讨组合型人工肾治疗尿毒症患者皮肤瘙痒的效果及护理方法。方法选择50例尿毒症伴皮肤瘙痒的维持性血液透析患者,随机分成对照组与观察组各25例,分别采用组合型人工肾治疗与常规血液透析8周。治疗前后检测甲状旁腺素水平,观察皮肤瘙痒改善情况。结果观察组治疗后甲状旁腺素水平显著低于对照组,皮肤瘙痒改善情况显著优于对照组(P0.05,P0.01)。结论组合型人工肾能有效地清除甲状旁腺素等大中分子毒素,改善患者的皮肤瘙痒症状;透析中防止感染、凝血,正确回血等是其护理要点。     

不同血液净化治疗方法对终末期肾病难治性高血压患者的临床观察

目的 不同血液净化方法治疗维持性血液透析患者难治性高血压的疗效观察.方法 60例终未期肾病难治性高血压患者按随机数字表法分为血液透析组,血液透析联合血液透析滤过组,血液透析联合血液灌流组,每组15例患者.血液透析联合血液透析滤过再联合血液灌流组,观察治疗前及治疗16周后所有患者血压变化及肾素、血管紧张素Ⅱ、全段甲状旁腺激素的水平变化.结果 各组患者治疗后血压及肾素、血管紧张素Ⅱ、全段甲状旁腺激素水平与治疗前比较差异有统计学意义(P＜0.05),而治疗组中血液透析联合血液透析滤过再联合血液灌流组与血液透析联合血液灌流组、血液透析联合血液透析滤过组治疗后比较,血压变化及肾素、血管紧张素Ⅱ、全段甲状旁腺激素水平与治疗前比较差异有统计学意义(P＜0.05).结论 在维持血液透析的治疗基础上联合应用血液透析滤过及血液灌流能有效的控制终未期肾病难治性高血压.     

组合型人工肾治疗尿毒症患者皮肤瘙痒的效果观察

目的探讨组合型人工肾治疗尿毒症患者皮肤瘙痒的效果及护理方法。方法选择50例尿毒．症伴皮肤瘙痒的维持性血液透析患者,随机分成对照组与观察组各25例,分别采用组合型人工肾治疗与常规血液透析8周。治疗前后检测甲状旁腺素水平,观察皮肤瘙痒改善情况。结果观察组治疗后甲状旁腺素水平显著低于对照组,皮肤瘙痒改善情况显著优于对照组（P〈0．05,P〈0．01）。结论组合型人工肾能有效地清除甲状旁腺素等大中分子毒素,改善患者的皮肤瘙痒症状;透析中防止感染、凝血,正确回血等是其护理要点。     

胜湿止痒汤组方联合组合型人工肾治疗尿毒症皮肤瘙痒疗效观察

目的:观察自拟胜湿止痒汤组方药浴联合组合型人工肾治疗尿毒症皮肤瘙痒患者的治疗效果.方法:选择我院长期行血液透析伴皮肤瘙痒患者80例,随机分成两组,对照组予纠正贫血,维持水电解质及酸碱平衡、控制饮食等常规治疗,组合型人工肾(血液透析器串联血液灌流器).治疗组在对照组治疗基础上加用自拟胜湿止痒汤组方药浴治疗.结果:与对照组比较,治疗组患者皮肤瘙痒无论从缓解程度及睡眠质量改善程度上均有明显效果,差异均具有显著性(P＜0.05).结论:应用自拟胜湿止痒汤组方药浴联合组合型人工肾治疗尿毒症皮肤瘙痒疗效显著.     

组合型人工肾对维持性血液透析患者矿物质代谢的影响

目的探讨组合型人工肾技术对维持性血液透析(maintenance hemodialysis,MHD)患者矿物质代谢的影响。方法选择2012年1月至2013年8月在新乡市血液净化中心行MHD治疗3个月或以上的患者110例。按照随机数字表法将110例患者分为常规血液透析(hemodialysis,HD)组55例和组合型人工肾组55例。HD组患者每周行3次血液透析治疗,而组合型人工肾组患者每周行2次常规HD治疗加1次组合型人工肾治疗[将HD管路与血液灌流(hemoperfusion,HP)管路串联,选用透析模式,2 h后用盐水将灌流器及管路的血冲洗干净后迅速撤掉,再继续进行2 h的HD]。监测治疗前和治疗3个月后MHD患者外周血中血钙、血磷、血全段甲状旁腺素(intact parathyroid hormone,iPTH)及碱性磷酸酶(alkaline phosphatase,ALP)等矿物质代谢的评估指标。结果2组患者治疗前血钙、血磷、iPTH及ALP水平比较,差异无统计学意义(均P0.05)。治疗3个月后,HD组血钙、iPTH和血ALP与治疗前比较,差异无统计学意义(均P0.05);而血磷低于治疗前水平,差异有统计学意义(P0.05)。组合型人工肾组治疗后血磷、iPTH和血ALP较治疗前均明显下降(P均0.01),血钙明显上升(P0.05)。2组治疗后比较,组合型人工肾组的血钙水平较HD组明显升高(P0.05),ALP明显降低(P0.05),而血磷、iPTH明显降低(P0.01)。结论与常规血液透析比较,组合型人工肾治疗能有效清除血磷,降低血iPTH和ALP,升高血钙水平,从而改善MHD患者的矿物质代谢异常。     

组合型人工肾在透析患者肾性贫血中的疗效观察

目的:探讨组合型人工肾(HP/HD)在治疗血液透析患者肾性贫血中的临床疗效。方法:将维持性血液透析1年以上的患者60例随机分为普通透析HD组30例,组合型人工肾(HP/HD)组30例。HD组采取维持性HD治疗,每周透析3次,每次透析4h,组合型人工肾(HP/HD)组每周行1次HP/HD,HD治疗2次,时间均4 h。所有患者均在上机治疗前后及6个月后空腹采血,观察两组各项指标的变化。结果:治疗后组合型人工肾(HP/HD)组中大分子量毒素β2-MG、iPTH与HD组比较明显下降,与HD组比较Hb明显升高,有统计学差异(P<0.05)。结论:组合型人工肾(HP/HD)增加了对中大分子量毒素的清除,治疗肾性贫血效果优于普通HD。     

连续性血液净化治疗尿毒症难治性高血压疗效观察

目的：观察连续性血液净化（CBP）治疗尿毒症并发难治性高血压（RH）患者的临床疗效。方法：回顾性分析32例尿毒症合并RH患者经CBP治疗后血压控制情况及治疗前后血肾素、血管紧张素Ⅱ、甲状旁腺素水平以及尿量、体重改变。结果：32例患者经过CBP治疗后收缩压、舒张压、平均动脉压、血肾素、血管紧张素Ⅱ、甲状旁腺素水平均较治疗前明显降低,体重较前亦有所下降,差异均有统计学意义（P〈0.05）,尿量变化差异无统计学意义（P〉0.05）,血压均控制在正常范围。结论：尿毒症患者RH的发生与容量负荷过重,肾素-血管紧张素系统过度活跃以及继发性甲旁亢等有关,CBP为一有效的控制尿毒症患者高血压的方法。     

组合型人工肾在临床中应用

人工肾主要用于治疗肾功能衰竭引起的尿毒症.随着高新技术和透析原理的深人研究,人工肾技术目前已从血液透析演变为血液净化,不断衍生出新的治疗技术和模式,拓宽了其临床应用范围.组合型人工肾成为血液净化发展的趋势,本文就组合型人工肾的临床应用现状作一简述.     

维持性血液透析患者血管活性物质的动态变化

近年来 ,慢性肾衰竭 (ＣＲＦ)患者的残余肾功能 (ＲＲＦ)越来越受到重视。肾素 (ＰＲＡ)、血管紧张素 (ＡⅡ )、心钠素(ＡＮＰ)及内皮素 (ＥＴ)等都对肾脏的病理生理变化有较大影响〔1〕,因此 ,我们对ＣＲＦ维持性血液透析 (ＣＨＤ)患者血管活性物质的动态变化做了对比观察 ,以     

血液灌流在维持性血液透析并发难治性高血压治疗中的临床疗效观察

目的观察血液灌流（hemoperfusion,HP）对维持性血液透析（hemodiaIysis,HD）患者并发难治性高血压的治疗作用并探讨其可能的致病机制。方法将58例符合难治性高血压的维持性HD患者随机分为治疗组30例及对照组28例,治疗组在HD基础上进行HP治疗,每2周1次,每次2．5h,持续12周,对照组仅行HD治疗。观察两组治疗前、后血压变化,降压药使用种类以及血浆肾素活性（plasmareninactivity,PRA）、血管紧张素（angiotensin,Ang）Ⅱ、醛固酮（aldosterone,Ald）、内皮素（endothelin,ET）、全段甲状旁腺素（intactparathyroidhormone,i-PTH）等物质的水平。结果维持性HD并发难治性高血压患者体内存在较高水平的PRA、AngⅡ、Ald、ET、i-PTH,12周后治疗组PRA、AngⅡ、Aid、ET、i-PTH较治疗前以及对照组明显下降,差异有统计学意义（P〈0．05）,而对照组治疗前、后各项指标无明显变化（P〉0．05）,治疗组血压下降,使用降压药种类减少,与治疗前及对照组比较,差异有统计学意义（P〈0．05）,而对照组治疗前、后血压无明显变化（P〉0．05）。结论HP对维持性HD伴难治性高血压患者有显著的治疗作用。这与HP有效的清除尿毒症患者体内PRA、AngⅡ、Ald、ET、i-PTH等中、大分子物质有关。     

血管紧张素Ⅱ受体拮抗影响肝纤维化的实验研究

目的 观察血管紧张素Ⅱ及其受体拮抗剂对体外培养的肝星状细胞合成转化生长因子-β1(TGF-β1),以及金属蛋白酶组织抑制因子-1(TIMP-1)mRNA表达的影响. 方法 采用HSC-T6肝星状细胞系作为活化的肝星状细胞的研究模型.将培养的肝星状细胞随机分为对照组、血管紧张素Ⅱ(AngⅡ)组、受体拮抗剂(AT1RA)组和血管紧张素Ⅱ+受体拮抗剂(AngⅡ+AT1RA)组.采用ELISA法检测细胞培养上清液中TGF-β1蛋白的含量.RT-PCR法检测肝星状细胞中TIMP-1 mRNA的表达. 结果 细胞培养上清液中TGF-β1蛋白的含量,对照组、AngⅡ组和AngⅡ+AT1RA组分别为(7.531±0.654)pg/mL、(9.855±1.485)pg/mL和(7.719±0.329)pg/mL,AngⅡ组高于对照组(P＜0.05),AngⅡ+AT1RA组显著低于AngⅡ组(P＜0.05).肝星状细胞TIMP-1mRNA的表达水平,对照组、AngⅡ组和AngⅡ+AT1RA组分别为3.387±0.042、4.870±0.061和3.837±0.042,AngⅡ组高于对照组(P＜0.05),AngⅡAT1RA组显著低于AngⅡ组(P＜0.05). 结论 血管紧张素Ⅱ能够促进肝星状细胞TGF-β1蛋白的合成以及TIMP-1 mRNA的表达,而血管紧张素Ⅱ1型受体拮抗剂能够明显抑制这一作用.     

不同血液净化方式联合骨化三醇冲击治疗对维持性血液透析患者肾性骨病指标的影响及意义

目的 通过观察不同血液净化方式联合骨化三醇冲击治疗对维持性血液透析患者肾性骨病指标的影响,探讨肾性骨病合适的治疗方案.方法 将60例符合标准的患者按随机数字表法分为3组,每组20例.所有患者采用骨化三醇冲击治疗,使用低钙透析液.普通透析组患者采用常规透析,血液透析滤过组患者采用血液透析滤过治疗,每周透析3次,其中血液透析滤过治疗每周1次.血液透析灌流组患者采用血液透析联合血液灌流治疗,每周透析3次,其中血液透析联合血液灌流治疗每周1次.结果 3组患者使用不同透析方式联合药物治疗3个月后发现,治疗前3组患者血钙、血磷、血甲状旁腺激素水平比较差异无统计学意义(P＞0.05),治疗后1个月血液透析灌流组患者血磷与普通透析组患者比较差异有统计学意义(P＜0.05),而血液透析滤过组患者的血磷与普通透析组比较差异无统计学意义(P＞0.05);治疗后3个月血液透析滤过组和血液透析组患者的血甲状旁腺激素、血磷、血钙水平与普通透析组比较差异也有统计学意义(P＜0.05),而血液透析滤过组和血液透析灌流组间血甲状旁腺激素、血磷、血钙水平比较差异无统计学意义(P＞0.05).结论 对于维持性血液透析的患者存在高磷血症以及继发性甲状旁腺激素的升高等肾性骨病的指标异常,可以应用血液透析滤过以及血液透析联合血液灌流治疗,且安全可行.     

维持性血液透析联合血液灌流：一种安全有效的模式

目的 探讨维持性血液透析（MHD）联合血液灌流（HP）治疗能否提高中、大分子毒素的清除率,能否改善MHD患者的生活质量并降低其病死率。 方法 采用前瞻性、随机、对照性研究。选取100例MHD患者,4周试验导入期后随机分为2组。HD+HP组（n=51）采取维持性单纯血液透析（2次/周）和HD+HP（1次/周）治疗;HD组（n=49）采取单纯血液透析（3次/周）治疗。平均随访2年。主要观察终点为患者死亡;次要观察终点为常规临床指标、瘦素、超敏C反应蛋白（hsCRP）、白细胞介素6（IL-6）、β2微球蛋白（β2-MG）、甲状旁腺激素（PTH）、肿瘤坏死因子α（TNF-α）和SF-36量表生活质量指数。 结果 2年观察期结束时,HD+HP组患者的瘦素、hsCRP、PTH、IL-6、β2-MG和TNF-α 的血清浓度和收缩压、舒张压、心率、心胸比、左室质量指数（LVMI）、EPO剂量和降压药的种类均低于HD组（均P < 0.05）;HD+HP组患者的血红蛋白（Hb）浓度、左心室射血分数（EF）、体质量指数（BMI）均高于HD组（均P < 0.05）;2组患者的血清白蛋白（Alb）浓度、血清铁（SI）浓度、总铁结合力（TIBC）、Kt/V、每分心输出量（CO）和二尖瓣峰值流速比（E/A）差异均无统计学意义。2年观察期结束后,SF-36量表显示HD+HP组患者的生活质量明显好于HD组,总评价值显示HD+HP组患者总分高于HD组（P < 0.05）。2年观察期间的Kaplan-Meier生存曲线显示HD+HP组患者具有明显的生存优势,Log-rank检验P < 0.05。HD+HP组患者行HD+HP时未发生严重的不良反应。 结论 HD+HP清除患者体内中大分子毒素的效果明显优于单纯性HD,同时在改善MHD患者的生活质量和提高其生存率方面有潜在的优势。     

Effects of B7-1 on the cytoskeleton rearrangement in podocytes induced by angiotensin Ⅱ

Objective To observe the effect of costimulatory molecule B7-1 on cytoskeleton rearrangement in mouse podocytes induced by angiotensinⅡ(AngⅡ), and to study the underlying molecular mechanism of B7-1 in the pathological changes of podocytes. Methods All cultivation of conditionally immortalized mouse podocytes (MPC) in vitro were divided into the following groups: normal control group, CTLA-4 group, AngⅡgroup (10-6 mmol/L 12 h, 24 h; 10-8 mmol/L 12 h, 24 h) and CTLA-4 with AngⅡgroup. Transfect B7-1 RNA interference fragment (siRNA) to the mature podocytes, and then restimulated by AngⅡ(10-6 mmol/L 12 h), the change of podocyte cytoskeleton after AngⅡ stimulation were observed. The expression of B7-1 in each group was assayed by flow cytometry and Western blotting. The nephrin and p-nephrin protein levels in the four groups were also analyzed by Western blotting. At the same time, the podocyte cytoskeleton distribution as indicated by F-actin was observed by fluorescence microscopy. Results Flow cytometry and Western blotting showed that B7-1 was not expressed in the normal control group. AngⅡshowed a concentration and time dependent induction of B7-1 expression in mouse podocytes (P＜0.05). Western blotting indicated that AngⅡinduced B7-1 protein expression (P＜0.05). Expression of nephrin and p-nephrin was significantly down-regulated by AngⅡ(P＜0.05). Compared with the normal control group, the expression of podocyte protein nephrin and p-nephrin in Ang II stimulation group was significantly reduced (P＜0.05). Using FITC phalloidin fluorescence staining showed that CTLA-4+AngⅡ stimulation group cytoskeleton rearrangement was improved significantly and F-actin recombinant score (mCFS) decreased compared with AngⅡ group (P＜0.05), suggesting that AngⅡ led to the disorder of the podocytes cytoskeleton and the destruction of the cytoskeleton of podocytes by AngⅡ could be improved after B7-1 blocking. Compared with the AngⅡ stimulation, transfection of B7-1 siRNA+AngⅡ stimulation group improved F-actin cytoskeletal rearrangement, and mCFS also decreased significantly (P＜0.05), suggesting that transfection of B7-1 siRNA might improve the damage of AngⅡ on podocytes cytoskeleton. Conclusions B7-1 participates in the process of cytoskeleton reconstruction and plays an important role in the pathological changes of podocytes.     

Role of ABCA1 in angiotensinⅡ-induced cholesterol accumulation in podocytes

Objective To investigate the effects of angiotensinⅡ(AngⅡ) on the expression of ATP-binding cassette transporter A1(ABCA1) in AngⅡ-infused rat model and cultured human podocytes, and to explore the role of ABCA1 in AngⅡ-induced cholesterol accumulation of podocytes. Methods Twelve Wistar rats were randomly subjected to normal saline infusion, or AngⅡ infusion at 400 ng?kg-1?min-1 (via subcutaneous osmotic minipumps) for 8 weeks. The expression of glomerular ABCA1 was analyzed by Western blotting and real-time fluorescent quantitative PCR. In vitro, conditionally immortalized human podocytes were divided into normal group, AngⅡ group, AngⅡ+scrambled siRNA group, AngⅡ+ABCA1 siRNA group. The expression of podocyte ABCA1 was assessed by immunofluorescence, Western blotting and real-time fluorescent quantitative PCR. Oil Red O staining was used to observe the lipid droplets in podocytes and cholesterol efflux assay kit was used to measure the cholesterol efflux rate of podocytes. Fluorescein isothiocyanate (FITC)-conjugated phalloidin was used to observe the podocyte cytoskeleton. Results In vivo, compared with normal group, the protein and mRNA expression of glomerular ABCA1 in AngⅡ-infused rats were decreased (P＜0.05). In vitro, ABCA1 was distributed in the cytomembrane of podocytes, and compared with normal group, AngⅡtreatment down-regulated the expression of ABCA1 (P＜0.05). Increased lipid droplets, decreased cholesterol efflux and cytoskeletal rearrangement were observed in AngⅡ-treated podocytes. When compared to AngⅡ group, podocytes stimulated by AngⅡand then transfected with ABCA1 siRNA had lower expression level of ABCA1 mRNA and protein (all P＜0.05). More lipid droplets and lower cholesterol efflux rate could be observed in AngⅡ+ABCA1 siRNA group (P＜0.05). Conclusion The reduced expression of ABCA1 may be involved in AngⅡ-induced cholesterol accumulation in podocytes.     

不同血液净化方式对尿毒症透析患者血中细胞因子清除的临床应用

目的 研究不同血液净化方式对尿毒症透析患者血中细胞因子的清除效果.方法 将2006年4月至2009年2月在我院血液净化中心透析的45例患者按随机数字表法分为(1)血液透析联合血液灌流组;(2)血液透析滤过组;(3)HD组,血液透析组,每组15例.血液透析联合血液灌流组、血液透析滤过组每周治疗1次,每组患者治疗3次,中间间隔1周,第1次及第3次治疗前、后各从动脉端采血5 ml,并留取正常健康对照组血液,整批送检.测定治疗前、后血清细胞因子的浓度.结果 血液灌流联合血液透析组、血液透析滤过组及血液透析组治疗前、后白细胞介素1β、白细胞介素6、肿瘤坏死因子α浓度与健康对照组比较差异有统计学意义(P＜0.01);血液透析组患者血肿瘤坏死因子α、白细胞介素1β、白细胞介素6水平分别为(3±10)ng/L、(4±9)ng/L、(4±9)ng/L,治疗前、后差值比较分别为176.0%、141.0%、187.0%,血液透析滤过组血肿瘤坏死因子α、白细胞介素1β、白细胞介素6水平分别为(39±15)ng/L、(36±14)ng/L、(45±16)ng/L,治疗前后差值比较分别为24.6%、22.1%、29.8%,血液灌流联合血液透析组血肿瘤坏死因子α、白细胞介素1β、白细胞介素6水平分别为(48±16)ng/L、(38±15)ng/L、(50±14)ng/L,治疗前差值比较分别为27.8%、23.9%、32.3%,3组患者血肿瘤坏死因子α、白细胞介素1β、白细胞介素6水平间比较差异有统计学意义(t分别=17.39、11.24、21.89,P均＜0.01).结论 不同的血液净化方式对各类细胞因子的清除效果不同,其中液灌流联合血液透析组及血液透析滤过组治疗埘细胞因子清除有效,血液透析组治疗对细胞因子清除基本无效,液灌流联合血液透析组及血液透析滤过组细胞因子清除效果与血液透析滤过组比较差异无统计学意义(P＞0.05).     

Effects of 12-lipoxygenase and angiotensinⅡ on p21, p27 and p57 in rat diabetic glomeruli

Objective To investigate the effects of 12-lipoxygenase (12-LO) and angiotensin Ⅱ(AngⅡ) on the CIP/KIP family of cyclin-dependent kinase inhibitors (CKIs) p21, p27 and p57 related to cell hypertrophy. Methods Mesangial cells were treated with high glucose for 24 hours and 48 hours respectively. 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] and AngⅡ were infused to rats by osmotic mini-pump for 1 week and 2 weeks respectively. Rats fed high fat diet were received low dose streptozotocin (STZ) to make type 2 diabetes (DN). The rats were divided into normal control group, DN group, DN+AngⅡ type 1 receptor blocker (ARB) group or 12-LO inhibitor (CDC) group. DN+ARB rats were treated by losartan for 6 weeks, and DN+CDC rats were treated for 8 weeks. Urine albumin and protein expressions of p21, p27 and p57 were detected by ELISA and Western blotting respectively. Glomeruli injury and expressions of p21 and p27 were detected by PAS staining and immunohistochemistry respectively. Results High glucose increased p21 and p27 protein expression in mesangial cells significantly compared with the relative control (all P＜0.05), but had no effect on p57. AngⅡ increased p27 protein expression in glomeruli significantly (P＜0.05), but had no effect on p21 and p57 protein expression. 12(S)-HETE increased both p21 and p27 protein expression in glomeruli significantly (all P＜0.05), but had no effect on p57 protein expression. Blood glucose, kidney/body weight, urinary protein, and glomerular p21 and p27 protein expressions were increased in DN group (all P＜0.05) compared with those in control group, with little change of p57 protein expression (P＜0.05). Moreover, glomerular hypertrophy and extra cellular matrix accumulation were observed in DN group. However, urine protein,kidney/body weight, renal injury, but not blood glucose, were decreased in DN+ARB group and DN+CDC group compared with DN group respectively (P＜0.05). Further DN+CDC rats had decreased both p21 and p27 protein expressions in glomeruli, but DN+ARB rats only had decreased p27 protein expression (all P＜0.05). Conclusions 12-LO may induce both p21 and p27 protein expression in DN glomeruli,but AngⅡ may induce only p27 expression.     

AngiotensinⅡ promotes the expression of glomerular IQGAP1 and apoptosis of glomerular cells

Objective To evaluate the effects of AngⅡ on the expression of IQ domain GTPase-activating protein1 (IQGAP1) and apoptosis of glomerular cells, and to explore the role of IQGAP1 in AngⅡ-induced apoptosis of glomerular cells. Methods Thirty-six male Wistar rats were randomly assigned to receive either saline or AngⅡ by osmotic mini-pump, or be used as normal control. The systolic blood pressure and proteinuria were measured at day 7, 14, 21, 28. After the animals were sacrificed at day 14, 28 respectively, the kidneys were collected. Renal pathological change, glomerular cell apoptosis were observed. The expression of glomerular IQGAP1 was assessed by immunohistochemistry, immunofluorescence and Western blotting. The activation of caspase-3 and phosphorylation of extracellular regulated protein kinases 1 and 2 (ERK1/2) were determined by Western blotting. Results AngⅡ-infused rats developed significant hypertension and marked proteinuria. Mild glomerular mesangial cell proliferation and mesangial matrix increase were also observed in AngⅡ-infused rats. The number of apoptotic glomerular cells in AngⅡ-infused rats was significantly more than that in normal control (P＜0.05). The expression of IQGAP1 in glomeruli distributed linearly along the capillary loops. AngⅡ infusion up-regulated the expression of glomerular IQGAP1, which had an significantly positive correlation with activation of caspase-3(r＝0.689, P＜0.05) and phosphorylation of ERK1/2 (r＝0.658, P＜0.05). Conclusion The enhanced expression of IQGAP1 may be involved in AngⅡ-induced glomerular cells apoptosis via activation of ERK1/2 signaling pathway.